Inspire Medical Systems, Inc. (INSP) - Stock Analysis

Last updated: Sep 6, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.

Loading chart data...

Idea window: 12/2/2025 – 12/9/2025Sector: Healthcare

AI Analyst Overview

Last Price
$73.00
Market Cap
$2.11B
1D Return
+7.16%
YTD Return
-20.85%

Loading chart data...

Valuation Metrics

P/E
15.7
P/B
2.5
P/S
2.4
EV/EBITDA
25.4
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Strong Liquidity Position • Quarterly Margin Compression • Rising Working Capital INSP has strong liquidity and 2025 profitability at a moderate valuation, but the sharp quarterly earnings slowdown and elevated working capital warrant caution.

StrongBalanceSheet
ProfitabilityRisk

Price Behavior

6.0

Key Price Behavior Insights: • Higher short-term lows • Resistance test • Elevated momentum Support Level: $61.40–$61.80 Resistance Level: $63.00–$64.00 INSP gained 4.9% over the last month and holds above its short-term average, but traders should watch $63–$64 resistance as RSI near 68 raises pullback risk.

Bullish
Resistance

Sentiment & News

6.0

Key News Insights: • Inspire V adoption • Mixed institutional flows • Reimbursement pressure Inspire Medical Systems shows strong adoption-driven momentum and investor interest, though reimbursement risks and post-earnings weakness warrant monitoring.

INSP
ReimbursementRisk
AI

AI Summary

6.0
Neutral

INSP is an execution-and-reimbursement recovery trade—not a proven return to growth—so investors should await sustained procedure-volume improvement and successful Inspire V adoption before underwriting a re-rating, despite strong liquidity and cash generation that limit downside funding risk.

ReimbursementRecovery
ExecutionRisk
InspireV
AI summary updated 5 days ago

Description

Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 2Dec 9INSPInspire Medical Systems, Inc.
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Closed+5.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.